The History of Testosterone and the Evolution of its Therapeutic Potential
- PMID: 29661690
- DOI: 10.1016/j.sxmr.2018.03.002
The History of Testosterone and the Evolution of its Therapeutic Potential
Abstract
Introduction: Testosterone therapy has been controversial since its synthesis in the 1930s to the present day. Testosterone's history provides depth and context for current controversies.
Aim: To review the history of testosterone therapy from its initial synthesis in the 1930s to the modern day.
Methods: Expert review of the literature.
Main outcome measures: Impactful events in the history of testosterone.
Results: By the 1940s there was already a fascinating literature that described the many symptomatic benefits of testosterone therapy that are recognized today. Numerous early reports suggested testosterone therapy improved angina pectoris and peripheral vascular disease. The assertion by Huggins and Hodges (Cancer Res 1941;1:293-297) in 1941 that testosterone activated prostate cancer (PCa) cast a pall for the next 70 years. The introduction of the radioimmunoassay in the 1970s shifted the diagnosis of testosterone deficiency from signs and symptoms to an undue emphasis on blood test results. The fear of PCa was the primary obstacle to the adoption of testosterone therapy for decades. Prescription rates increased as accumulated evidence showed testosterone therapy was not associated with increased PCa risks. The observation that androgenic stimulation of PCa reaches a maximum at relatively low testosterone concentrations-the saturation model-provided the theoretical framework for understanding the relation between androgens and PCa and led to multiple case series documenting reassuring results of testosterone therapy in men with PCa. Recent concerns regarding cardiovascular risks also have diminished because new evidence suggests testosterone therapy might actually be cardioprotective. In 2016 the Testosterone Trials provided high-quality evidence of multiple benefits of testosterone therapy, nearly all of which had been recognized by clinicians by 1940.
Conclusions: If the past has any lessons for the future, it is likely that research will continue to demonstrate health benefits of testosterone therapy, while it remains one of the most controversial topics in medicine. Morgentaler A, Traish A. The History of Testosterone and the Evolution of its Therapeutic Potential. Sex Med Rev 2020;8:286-296.
Keywords: Androgens; Deficiency; Hypogonadism; Prostate Cancer; Saturation; Testosterone.
Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
A new era of testosterone and prostate cancer: from physiology to clinical implications.Eur Urol. 2014 Jan;65(1):115-23. doi: 10.1016/j.eururo.2013.08.015. Epub 2013 Aug 16. Eur Urol. 2014. PMID: 24011426 Review.
-
Testosterone and prostate cancer: revisiting old paradigms.Eur Urol. 2009 Jul;56(1):48-56. doi: 10.1016/j.eururo.2009.03.088. Epub 2009 Apr 8. Eur Urol. 2009. PMID: 19375844 Review.
-
Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.Sex Med Rev. 2019 Oct;7(4):636-649. doi: 10.1016/j.sxmr.2019.06.003. Epub 2019 Jul 24. Sex Med Rev. 2019. PMID: 31351915 Review.
-
Testosterone Therapy and Prostate Cancer.Urol Clin North Am. 2016 May;43(2):209-16. doi: 10.1016/j.ucl.2016.01.007. Urol Clin North Am. 2016. PMID: 27132578 Review.
-
Is testosterone a friend or a foe of the prostate?J Sex Med. 2011 Apr;8(4):946-55. doi: 10.1111/j.1743-6109.2011.02233.x. J Sex Med. 2011. PMID: 21457469 Review.
Cited by
-
Interplay between androgen and CXCR4 chemokine signaling in myelin repair.Acta Neuropathol Commun. 2024 Jan 30;12(1):18. doi: 10.1186/s40478-024-01730-1. Acta Neuropathol Commun. 2024. PMID: 38291527 Free PMC article.
-
The immune and metabolic treatment approach of using testosterone on mice models of liver injury.Front Pharmacol. 2023 Aug 8;14:1219709. doi: 10.3389/fphar.2023.1219709. eCollection 2023. Front Pharmacol. 2023. PMID: 37614321 Free PMC article.
-
Testosterone promotes the migration, invasion and EMT process of papillary thyroid carcinoma by up-regulating Tnnt1.J Endocrinol Invest. 2024 Jan;47(1):149-166. doi: 10.1007/s40618-023-02132-1. Epub 2023 Jul 21. J Endocrinol Invest. 2024. PMID: 37477865 Free PMC article.
-
The complications of male hypogonadism: is it just a matter of low testosterone?Front Endocrinol (Lausanne). 2023 Jun 28;14:1201313. doi: 10.3389/fendo.2023.1201313. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37455904 Free PMC article. Review.
-
Recognizing the True Value of Testosterone Therapy in Health Care.Androg Clin Res Ther. 2022 Dec 28;3(1):217-223. doi: 10.1089/andro.2022.0021. eCollection 2022. Androg Clin Res Ther. 2022. PMID: 36643964 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
